AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.
Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.
AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in recent years.
Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day.
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.
AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.
10,000 boomers are reaching retirement age every day. The 4% rule for retirement withdrawals may not always work due to sequence risk and market fluctuations. Building a dividend income snowball can provide a more stable retirement income, with 2 high-yielding recession-proof stock picks recommended.
Seasoned investors tend to closely follow the ups and downs of the market.
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.